Clinical Trials Browser

Phase 2 × Glutamine × Clear all

NCT01607879 2023-09-22

Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation

Phase 2 Completed

48 enrolled 15 charts

EndocrineGenitourinary

Prostatic Neoplasms, Multiple Endocrine Neoplasia Type 1

NCT01783522 2019-10-22

Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib

Phase 2 Terminated

9 enrolled 10 charts

Multiple Myeloma, Peripheral Nervous System Diseases

NCT02012608 2019-05-29

Glutamine for the Prevention of Radiation Toxicity in Subjects Conserving Therapy

Phase 2 Terminated

14 enrolled 5 charts

Breast Neoplasms

NCT00365768 2016-09-09

Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors

Phase 2 Completed

56 enrolled 5 charts

GenitourinaryLymphoidOther hematologic neoplasmSarcoma

Burkitt Lymphoma, Kidney Neoplasms, Leukemia, Lymphoma, Wilms Tumor, Peripheral Nervous System Diseases, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Neuroectodermal Tumors, Primitive, Peripheral, Neurotoxicity Syndromes, Lymphoma, Extranodal NK-T-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT00255229 2016-02-25

Study of Glutamine as Prophylaxis for Irinotecan Induced Diarrhea

Phase 2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT01157039 2016-02-24

A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin

Phase 2 Withdrawn

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT02114502 2014-07-11

Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma

Phase 2 Withdrawn

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00003898 2011-03-01

Glutamine in Treating Side Effects in Children Who Are Undergoing Stem Cell Transplantation

Phase 2 Completed

Other solid neoplasm

Oral Complications